Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| flibanserin flexible dose | Experimental | Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| flibanserin flexible dose | Drug | Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site. |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of Adverse Events | 28 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sprout Pharmaceuticals | Sprout Pharmaceuticals | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 511.118.43005 Boehringer Ingelheim Investigational Site | Innsbruck | Austria | ||||
| 511.118.43002 Boehringer Ingelheim Investigational Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Flibanserin Flexible Dose | Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 for safety/tolerability or later in the study at any time following patient contact with the site. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Vienna |
| Austria |
| 511.118.43004 Boehringer Ingelheim Investigational Site | Vienna | Austria |
| 511.118.43006 Boehringer Ingelheim Investigational Site | Wörgl | Austria |
| 511.118.32004 Boehringer Ingelheim Investigational Site | Braine-l'Alleud | Belgium |
| 511.118.32003 Boehringer Ingelheim Investigational Site | Edegem | Belgium |
| 511.118.32005 Boehringer Ingelheim Investigational Site | Ghent | Belgium |
| 511.118.32006 Boehringer Ingelheim Investigational Site | Hasselt | Belgium |
| 511.118.32002 Boehringer Ingelheim Investigational Site | Yvoir | Belgium |
| 511.118.42001 Boehringer Ingelheim Investigational Site | Olomouc | Czechia |
| 511.118.42002 Boehringer Ingelheim Investigational Site | Prague | Czechia |
| 511.118.42003 Boehringer Ingelheim Investigational Site | Prague | Czechia |
| 511.118.42004 Boehringer Ingelheim Investigational Site | Vřesina | Czechia |
| 511.118.35801 Boehringer Ingelheim Investigational Site | Espoo | Finland |
| 511.118.35805 Boehringer Ingelheim Investigational Site | Helsinki | Finland |
| 511.118.35802 Boehringer Ingelheim Investigational Site | Oulu | Finland |
| 511.118.35803 Boehringer Ingelheim Investigational Site | Seinäjoki | Finland |
| 511.118.35804 Boehringer Ingelheim Investigational Site | Tampere | Finland |
| 511.118.3308A Boehringer Ingelheim Investigational Site | Blanquefort | France |
| 511.118.3301A Boehringer Ingelheim Investigational Site | Bordeaux | France |
| 511.118.3305A Boehringer Ingelheim Investigational Site | La Rochelle | France |
| 511.118.3314A Boehringer Ingelheim Investigational Site | Lille | France |
| 511.118.3314B Cabinet médical | Lille | France |
| 511.118.3303A Boehringer Ingelheim Investigational Site | Marseille | France |
| 511.118.3310A Boehringer Ingelheim Investigational Site | Marseille | France |
| 511.118.3312A Boehringer Ingelheim Investigational Site | Marseille | France |
| 511.118.3315A Cabinet Médical | Rennes | France |
| 511.118.3306A Boehringer Ingelheim Investigational Site | Saint-Émilion | France |
| 511.118.3311A Boehringer Ingelheim Investigational Site | Toulouse | France |
| 511.118.49004 Boehringer Ingelheim Investigational Site | Berlin | Germany |
| 511.118.49001 Boehringer Ingelheim Investigational Site | Bonn | Germany |
| 511.118.49006 Boehringer Ingelheim Investigational Site | Dresden | Germany |
| 511.118.49008 Boehringer Ingelheim Investigational Site | Frankfurt | Germany |
| 511.118.49003 Boehringer Ingelheim Investigational Site | Freiburg im Breisgau | Germany |
| 511.118.49002 Boehringer Ingelheim Investigational Site | Hanover | Germany |
| 511.118.49005 Boehringer Ingelheim Investigational Site | Leipzig | Germany |
| 511.118.36001 Boehringer Ingelheim Investigational Site | Budapest | Hungary |
| 511.118.36005 Boehringer Ingelheim Investigational Site | Kecskemét | Hungary |
| 511.118.36003 Boehringer Ingelheim Investigational Site | Szeged | Hungary |
| 511.118.36004 Boehringer Ingelheim Investigational Site | Szentes | Hungary |
| 511.118.39004 Boehringer Ingelheim Investigational Site | Catania | Italy |
| 511.118.39001 Boehringer Ingelheim Investigational Site | Pavia | Italy |
| 511.118.39003 Boehringer Ingelheim Investigational Site | Torino | Italy |
| 511.118.31006 Boehringer Ingelheim Investigational Site | Almere Stad | Netherlands |
| 511.118.31001 Boehringer Ingelheim Investigational Site | Amsterdam | Netherlands |
| 511.118.31004 Boehringer Ingelheim Investigational Site | Apeldoorn | Netherlands |
| 511.118.31003 Boehringer Ingelheim Investigational Site | Bilthoven | Netherlands |
| 511.118.31007 Boehringer Ingelheim Investigational Site | Den Helder | Netherlands |
| 511.118.31005 Boehringer Ingelheim Investigational Site | Enschede | Netherlands |
| 511.118.31002 Boehringer Ingelheim Investigational Site | Nieuwegein | Netherlands |
| 511.118.34004 Boehringer Ingelheim Investigational Site | Barcelona | Spain |
| 511.118.34003 Boehringer Ingelheim Investigational Site | Manresa (Barcelona) | Spain |
| 511.118.34002 Boehringer Ingelheim Investigational Site | Mataró-Barcelona | Spain |
| 511.118.34001 Boehringer Ingelheim Investigational Site | Ourense | Spain |
| 511.118.46004 Boehringer Ingelheim Investigational Site | Kungsbacka | Sweden |
| 511.118.46009 Boehringer Ingelheim Investigational Site | Lund | Sweden |
| 511.118.46001 Boehringer Ingelheim Investigational Site | Stockholm | Sweden |
| 511.118.46006 Boehringer Ingelheim Investigational Site | Stockholm | Sweden |
| 511.118.46005 Boehringer Ingelheim Investigational Site | Uppsala | Sweden |
| 511.118.46003 Boehringer Ingelheim Investigational Site | Västerås | Sweden |
| 511.118.44009 Boehringer Ingelheim Investigational Site | Chorley | United Kingdom |
| 511.118.44004 Boehringer Ingelheim Investigational Site | Fisherwick, Lichfield | United Kingdom |
| 511.118.44008 Boehringer Ingelheim Investigational Site | Glasgow | United Kingdom |
| 511.118.44003 Boehringer Ingelheim Investigational Site | Headington, Oxford | United Kingdom |
| 511.118.44001 Boehringer Ingelheim Investigational Site | London | United Kingdom |
| 511.118.44002 Boehringer Ingelheim Investigational Site | London | United Kingdom |
| 511.118.44007 Boehringer Ingelheim Investigational Site | South Brent | United Kingdom |
| 511.118.44010 Boehringer Ingelheim Investigational Site | Waterloo, Liverpool | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Flibanserin Flexible Dose | Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 for safety/tolerability or later in the study at any time following patient contact with the site. flibanserin flexible dose: Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the pati |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | participants |
| ||||||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||||||||||
| Race/Ethnicity, Customized | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Frequency of Adverse Events | Posted | Number | participants with any adverse event | 28 weeks |
|
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Flibanserin Flexible Dose | Initial dosage: Patients were to take one 50 mg flibanserin tablet in the evening. Subsequent dosage titrations: Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient. Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY. Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site. | 9 | 480 | 275 | 480 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| gastroenteritis | Infections and infestations | Systematic Assessment |
| ||
| Breast Cancer in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Migraine with aura | Nervous system disorders | Systematic Assessment |
| ||
| Neuralgia | Nervous system disorders | Systematic Assessment |
| ||
| Abdominal pain | Gastrointestinal disorders | Systematic Assessment |
| ||
| Uterine polyp | Reproductive system and breast disorders | Systematic Assessment |
| ||
| ovarian cyst | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Exomphalos | Congenital, familial and genetic disorders | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Fatigue | Nervous system disorders | Systematic Assessment |
| ||
| Headache | Nervous system disorders | Systematic Assessment |
| ||
| Nasopharyngitis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Nausea | Gastrointestinal disorders | Systematic Assessment |
| ||
| Dizziness | Nervous system disorders | Systematic Assessment |
| ||
| Somnolence | Nervous system disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Krista Barbour, Ph.D. | Sprout Pharmaceuticals | 9198820850 | kbarbour@sproutpharma.com |
| ID | Term |
|---|---|
| D020018 | Sexual Dysfunctions, Psychological |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| 50 years and older |
|
| Black |
|
| Missing |
|
| Title | Measurements |
|---|---|
|
| patients with severe adverse events |
|
| patients with serious adverse events |
|